Epigenetic silencing of Na,K-ATPase β1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma

Epigenetics

Volumn 9, Issue 4, 2014, Pages 579-586

  Selvakumar, Ponniah ^a   Owens, Tori A ^a   David, Justin M ^a,b   Petrelli, Nicholas J ^c   Christensen, Brock C ^d   Lakshmikuttyamma, Ashakumary ^e   Rajasekaran, Ayyappan K ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ATP1B1; DNA methylation; Epigenetics; K ATPase; Na; Renal cell carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); VON HIPPEL LINDAU PROTEIN; ATP1B1 PROTEIN, HUMAN; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; MESSENGER RNA;

ARTICLE; ATP1B1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE CULTURE; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; KIDNEY TUMOR; METABOLISM; TUMOR CELL LINE;

AZACITIDINE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; KIDNEY NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84899146360     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.27795     Document Type: Article

References (41)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92; PMID:17287242; http://dx.doi.org/10.1093/ annonc/mdl498
2. Mancini V, Battaglia M, Ditonno P, Palazzo S, Lastilla G, Montironi R, Bettocchi C, Cavalcanti E, Ranieri E, Selvaggi FP. Current insights in renal cell cancer pathology. Urol Oncol 2008; 26:225-38; PMID:18452811; http://dx.doi.org/10.1016/j. urolonc.2007.05.017
3. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998; 22:200-9; PMID:9624531; http://dx.doi.org/10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#
4. Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, Bentley E, Affara NA, Ferguson-Smith MA, Maher ER. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and Br J Cancer 1994; 69:230-4; PMID:8297719; http://dx.doi.org/10.1038/bjc.1994.44
5. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994; 91:9700-4; PMID:7937876; http://dx.doi.org/10.1073/pnas.91.21.9700
6. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-20; PMID:8493574; http://dx.doi.org/10.1126/ science.8493574
7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-5; PMID:10353251; http://dx.doi.org/10.1038/20459
8. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14:4726-34; PMID:18676741; http://dx.doi.org/10.1158/1078-0432.CCR-07-4921
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-9; PMID:23792563; http://dx.doi.org/10.1038/ nature12222
10. Morris MR, Maher ER. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2010; 2:59; PMID:20815920; http://dx.doi.org/10.1186/gm180
11. Avissar-Whiting M, Koestler DC, Houseman EA, Christensen BC, Kelsey KT, Marsit CJ. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma. Epigenetics 2011; 6:703-9; PMID:21610323; http://dx.doi.org/10.4161/ epi.6.6.16158
12. Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, Woodward ER, Clarke N, Latif F, Maher ER. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 2012; 7:278-90; PMID:22430804; http://dx.doi.org/10.4161/ epi.7.3.19103
13. Rajasekaran SA, Barwe SP, Rajasekaran AK. Multiple functions of Na, K-ATPase in epithelial cells. Semin Nephrol 2005; 25:328-34; PMID:16139688; http:// dx.doi.org/10.1016/j.semnephrol.2005.03.008
14. Rajasekaran SA, Rajasekaran AK. Na, K-ATPase and epithelial tight junctions. Front Biosci (Landmark Ed) 2009; 14:2130-48; PMID:19273189; http:// dx.doi.org/10.2741/3367
15. Vagin O, Dada LA, Tokhtaeva E, Sachs G. The Na-K-ATPase α1β1 heterodimer as a cell adhesion molecule in epithelia. Am J Physiol Cell Physiol 2012; 302:C1271-81; PMID:22277755; http://dx.doi. org/10.1152/ajpcell.00456.2011
16. Therien AG, Blostein R. Mechanisms of sodium pump regulation. Am J Physiol Cell Physiol 2000; 279:C541-66; PMID:10942705
17. Rajasekaran SA, Ball WJ Jr., Bander NH, Liu H, Pardee JD, Rajasekaran AK. Reduced expression of beta-subunit of Na, K-ATPase in human clearcell renal cell carcinoma. J Urol 1999; 162:574-80; PMID:10411090; http://dx.doi.org/10.1016/ S0022-5347(05)68629-6
18. Rajasekaran SA, Palmer LG, Quan K, Harper JF, Ball WJ Jr., Bander NH, Peralta Soler A, Rajasekaran AK. Na, K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility. Mol Biol Cell 2001; 12:279-95; PMID:11179415; http://dx.doi.org/10.1091/mbc.12.2.279
19. Inge LJ, Rajasekaran SA, Yoshimoto K, Mischel PS, McBride W, Landaw E, Rajasekaran AK. Evidence for a potential tumor suppressor role for the Na, KATPase beta1-subunit. Histol Histopathol 2008; 23:459-67; PMID:18228203
20. Espineda CE, Chang JH, Twiss J, Rajasekaran SA, Rajasekaran AK. Repression of Na, K-ATPase beta1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell 2004; 15:1364-73; PMID:14699059; http://dx.doi.org/10.1091/mbc.E03-09-0646
21. Rajasekaran SA, Huynh TP, Wolle DG, Espineda CE, Inge LJ, Skay A, Lassman C, Nicholas SB, Harper JF, Reeves AE, et al. Na, K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther 2010; 9:1515-24; PMID:20501797; http://dx.doi.org/10.1158/1535-7163.MCT-09-0832
22. Rodrigues M, Balicki D, Newrock KM, Mukherjee BB. Lack of correlation between loss of anchorageindependent growth and levels of transformation-specific p53 protein in retinoic acid-treated F9 embryonal carcinoma cells. Exp Cell Res 1985; 156:22-30; PMID:2981174; http://dx.doi. org/10.1016/0014-4827(85)90258-7
23. Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, Steeg PS. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991; 65:25-35; PMID:2013093; http://dx.doi. org/10.1016/0092-8674(91)90404-M
24. Weinberg RA. Tumor suppressor genes. Science 1991; 254:1138-46; PMID:1659741; http://dx.doi. org/10.1126/science.1659741
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http:// dx.doi.org/10.1016/S0092-8674(00)81683-9
26. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12-27; PMID:22770212; http://dx.doi.org/10.1016/j. cell.2012.06.013
27. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-31; PMID:12424112; http://dx.doi.org/10.1093/ bioinformatics/18.11.1427
28. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxiainducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12:122-7; PMID:16341243; http://dx.doi.org/10.1038/ nm1337
29. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001; 293:1089-93; PMID:11498579; http://dx.doi. org/10.1126/science.1063443
30. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-63; PMID:15164071; http://dx.doi.org/10.1038/nature02625
31. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13:679-92; PMID:22945394; http:// dx.doi.org/10.1038/nrg3270
32. Balch C, Nephew KP. Epigenetic targeting therapies to overcome chemotherapy resistance. Adv Exp Med Biol 2013; 754:285-311; PMID:22956507; http:// dx.doi.org/10.1007/978-1-4419-9967-2_14
33. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821-6; PMID:8790415; http://dx.doi.org/10.1073/pnas.93.18.9821
34. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi. org/10.1038/ng.298
35. Vanderkraats ND, Hiken JF, Decker KF, Edwards JR. Discovering high-resolution patterns of differential DNA methylation that correlate with gene expression changes. Nucleic Acids Res 2013; 41:6816-27; PMID:23748561; http://dx.doi.org/10.1093/nar/ gkt482
36. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007; 27:157-69; PMID:17060462; http://dx.doi.org/10.1128/ MCB.00892-06
37. Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther 2013; 345:206-14; PMID:23461975; http://dx.doi.org/10.1124/ jpet.113.203471
38. Chik F, Szyf M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 2011; 32:224-32; PMID:20980350; http://dx.doi.org/10.1093/carcin/bgq221
39. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008; 283:36542-52; PMID:18984585; http://dx.doi.org/10.1074/jbc. M804578200
40. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, Kung AL. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 2009; 106:4260-5; PMID:19255431; http:// dx.doi.org/10.1073/pnas.0810067106
41. Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 2012; 31:776-86; PMID:21725364; http://dx.doi.org/10.1038/ onc.2011.266